Novacyt Akcija

Novacyt EPS

Novacyt (ALNOV.PA) Pelnas vienai akcijai (EPS) 2026-08-14 dieną yra −0,59 GBP. Praėjusiais metais Pelnas vienai akcijai (EPS) buvo −0,40 GBP — pokytis 47,60% (mažesnis).

EPS

−0,59GBP

YoY

47,60%

Paskutinį kartą atnaujinta:

Novacyt Pelnas vienai akcijai (EPS) yra 2026 −0,59 GBP. Novacyt Pelnas vienai akcijai (EPS) buvo 2025 −0,40 GBP. Tai sumažėjo 47,60% mažesnis lyginant su praėjusiais metais.
Access this data via the Eulerpool API

Novacyt Akcijų analizė

Ką veikia Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt yra viena populiariausių kompanijų Eulerpool.com.

Dažniausiai užduodami klausimai apie Novacyt akciją

Novacyt Pelnas vienai akcijai (EPS) 2026 m. yra −0,59 GBP.

Novacyt Pelnas vienai akcijai (EPS) pasikeitė nuo −0,40 GBP iki −0,59 GBP, tai atitinka 47,60% pokytį. Reikšmė yra mažesnis nei praėjusiais metais.

Eulerpool rasite visą Pelnas vienai akcijai (EPS) Novacyt istorinę raidą nuo 2006 m. – su metinėmis reikšmėmis, grafikais ir išsamiomis analizėmis.

Pelnas vienai akcijai matuoja to įmonės pelno dalį, kuri tenka kiekvienai išleistai akcijai. Tai pagrindinė metrika, skirta vertinti įmonės pelningumą.

EPS = Grynasis pelnas / Išleistos akcijos

Access this data via the Eulerpool API

Pelno ir nuostolių ataskaita — Novacyt

Visi pagrindiniai rodikliai — Novacyt